focus
Previous article:
Drug repurposing or repositioning? The language matters
Next article: Cassava reveals details — and problems — with Alzheimer's study
Next article: Cassava reveals details — and problems — with Alzheimer's study
hotspot
explore
-
Readout Newsletter: XBI biotech index, Akero Therapeutics
2025-08-26 02:36 -
Acelyrin, a rare IPO success, stumbles in its first big test
2025-08-26 02:25 -
Eli Lilly to pay $200M for Beam’s stake in gene
2025-08-26 01:55 -
Readout Newsletter: XBI biotech index, Akero Therapeutics
2025-08-26 01:50 -
Will the IRA bring competition to the biologics market?
2025-08-26 01:34 -
Popular nasal decongestant doesn't actually relieve congestion
2025-08-26 01:17